09:45 AM EST - BioVaxys Technology Corp : Announced the acceptance of an abstract related to the PESCO study, an investigator-initiated, open-label, non-randomized phase 1B/2 trial to evaluate the safety and efficacy of combination of BioVaxys' MVP-S with pembrolizumab (Keytruda™) and cyclophosphamide in patients with recurrent epithelial ovarian cancer for presentation at the American Society of Clinical Oncology Annual Meeting, taking place in Chicago, May 29th-June 6th, 2026. BioVaxys Technology Corp
shares C.BIOV are trading unchanged at $0.05.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=7463146874123489
